CD248-targeted BBIR-T cell therapy against late-activated fibroblasts in cardiac repair after myocardial infarction

Abstract Excessive cardiac fibrosis is a key cause of heart failure and adverse ventricular remodeling after myocardial infarction. The abnormally activated fibroblasts after scar maturation are the chief culprit. Single-cell RNA sequencing of mouse cardiac interstitial cells after myocardial infarc...

Full description

Saved in:
Bibliographic Details
Main Authors: Haiting Chen, Ke Hu, Qi Tang, Junzhuo Wang, Qianyu Gu, Jiayu Chen, Jiaxin Hu, Ningxin Peng, Meng Guo, Yaohui Jiang, Qingbo Xu, Jun Xie
Format: Article
Language:English
Published: Nature Portfolio 2025-03-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-025-56703-2
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849390967529930752
author Haiting Chen
Ke Hu
Qi Tang
Junzhuo Wang
Qianyu Gu
Jiayu Chen
Jiaxin Hu
Ningxin Peng
Meng Guo
Yaohui Jiang
Qingbo Xu
Jun Xie
author_facet Haiting Chen
Ke Hu
Qi Tang
Junzhuo Wang
Qianyu Gu
Jiayu Chen
Jiaxin Hu
Ningxin Peng
Meng Guo
Yaohui Jiang
Qingbo Xu
Jun Xie
author_sort Haiting Chen
collection DOAJ
description Abstract Excessive cardiac fibrosis is a key cause of heart failure and adverse ventricular remodeling after myocardial infarction. The abnormally activated fibroblasts after scar maturation are the chief culprit. Single-cell RNA sequencing of mouse cardiac interstitial cells after myocardial infarction depicts a late-activated fibroblast subpopulation F-Act and initially identifies its characteristic antigen CD248, which is also verified in human hearts. On this basis, we develop a CD248-targeted biotin-binding immune receptor T cell therapy against F-Act to correct cardiac repair disorders. In our study, the precise removal of F-Act after the scar matured effectively inhibits fibrotic expansion in the peri-infarct zone and improves cardiac function. This therapy provides an idea for the treatment of cardiac fibrosis and also promotes the application of engineered T cells to non-tumor diseases.
format Article
id doaj-art-b7fd28e657c2454cb9672252cd27caed
institution Kabale University
issn 2041-1723
language English
publishDate 2025-03-01
publisher Nature Portfolio
record_format Article
series Nature Communications
spelling doaj-art-b7fd28e657c2454cb9672252cd27caed2025-08-20T03:41:14ZengNature PortfolioNature Communications2041-17232025-03-0116111610.1038/s41467-025-56703-2CD248-targeted BBIR-T cell therapy against late-activated fibroblasts in cardiac repair after myocardial infarctionHaiting Chen0Ke Hu1Qi Tang2Junzhuo Wang3Qianyu Gu4Jiayu Chen5Jiaxin Hu6Ningxin Peng7Meng Guo8Yaohui Jiang9Qingbo Xu10Jun Xie11Department of Cardiology, National Cardiovascular Disease Regional Center for Anhui, the First Affiliated Hospital of Anhui Medical University, No.218 Jixi RoadDepartment of Cardiology, National Cardiovascular Disease Regional Center for Anhui, the First Affiliated Hospital of Anhui Medical University, No.218 Jixi RoadNHC Key Laboratory of Antibody Technique, Nanjing Medical University, No.101 Longmian RoadAffiliated Drum Tower Hospital, Medical School, Nanjing University, No.321 Zhongshan RoadAffiliated Drum Tower Hospital, Medical School, Nanjing University, No.321 Zhongshan RoadDepartment of Cardiology, National Cardiovascular Disease Regional Center for Anhui, the First Affiliated Hospital of Anhui Medical University, No.218 Jixi RoadCardiovascular Disease Center, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi Clinical College of Wuhan University, No.158 Wuyang RoadDepartment of Cardiology, National Cardiovascular Disease Regional Center for Anhui, the First Affiliated Hospital of Anhui Medical University, No.218 Jixi RoadAffiliated Drum Tower Hospital, Medical School, Nanjing University, No.321 Zhongshan RoadAffiliated Drum Tower Hospital, Medical School, Nanjing University, No.321 Zhongshan RoadDepartment of Cardiology, the First Affiliated Hospital, Zhejiang University School of Medicine, No.79 Qingchun RoadDepartment of Cardiology, National Cardiovascular Disease Regional Center for Anhui, the First Affiliated Hospital of Anhui Medical University, No.218 Jixi RoadAbstract Excessive cardiac fibrosis is a key cause of heart failure and adverse ventricular remodeling after myocardial infarction. The abnormally activated fibroblasts after scar maturation are the chief culprit. Single-cell RNA sequencing of mouse cardiac interstitial cells after myocardial infarction depicts a late-activated fibroblast subpopulation F-Act and initially identifies its characteristic antigen CD248, which is also verified in human hearts. On this basis, we develop a CD248-targeted biotin-binding immune receptor T cell therapy against F-Act to correct cardiac repair disorders. In our study, the precise removal of F-Act after the scar matured effectively inhibits fibrotic expansion in the peri-infarct zone and improves cardiac function. This therapy provides an idea for the treatment of cardiac fibrosis and also promotes the application of engineered T cells to non-tumor diseases.https://doi.org/10.1038/s41467-025-56703-2
spellingShingle Haiting Chen
Ke Hu
Qi Tang
Junzhuo Wang
Qianyu Gu
Jiayu Chen
Jiaxin Hu
Ningxin Peng
Meng Guo
Yaohui Jiang
Qingbo Xu
Jun Xie
CD248-targeted BBIR-T cell therapy against late-activated fibroblasts in cardiac repair after myocardial infarction
Nature Communications
title CD248-targeted BBIR-T cell therapy against late-activated fibroblasts in cardiac repair after myocardial infarction
title_full CD248-targeted BBIR-T cell therapy against late-activated fibroblasts in cardiac repair after myocardial infarction
title_fullStr CD248-targeted BBIR-T cell therapy against late-activated fibroblasts in cardiac repair after myocardial infarction
title_full_unstemmed CD248-targeted BBIR-T cell therapy against late-activated fibroblasts in cardiac repair after myocardial infarction
title_short CD248-targeted BBIR-T cell therapy against late-activated fibroblasts in cardiac repair after myocardial infarction
title_sort cd248 targeted bbir t cell therapy against late activated fibroblasts in cardiac repair after myocardial infarction
url https://doi.org/10.1038/s41467-025-56703-2
work_keys_str_mv AT haitingchen cd248targetedbbirtcelltherapyagainstlateactivatedfibroblastsincardiacrepairaftermyocardialinfarction
AT kehu cd248targetedbbirtcelltherapyagainstlateactivatedfibroblastsincardiacrepairaftermyocardialinfarction
AT qitang cd248targetedbbirtcelltherapyagainstlateactivatedfibroblastsincardiacrepairaftermyocardialinfarction
AT junzhuowang cd248targetedbbirtcelltherapyagainstlateactivatedfibroblastsincardiacrepairaftermyocardialinfarction
AT qianyugu cd248targetedbbirtcelltherapyagainstlateactivatedfibroblastsincardiacrepairaftermyocardialinfarction
AT jiayuchen cd248targetedbbirtcelltherapyagainstlateactivatedfibroblastsincardiacrepairaftermyocardialinfarction
AT jiaxinhu cd248targetedbbirtcelltherapyagainstlateactivatedfibroblastsincardiacrepairaftermyocardialinfarction
AT ningxinpeng cd248targetedbbirtcelltherapyagainstlateactivatedfibroblastsincardiacrepairaftermyocardialinfarction
AT mengguo cd248targetedbbirtcelltherapyagainstlateactivatedfibroblastsincardiacrepairaftermyocardialinfarction
AT yaohuijiang cd248targetedbbirtcelltherapyagainstlateactivatedfibroblastsincardiacrepairaftermyocardialinfarction
AT qingboxu cd248targetedbbirtcelltherapyagainstlateactivatedfibroblastsincardiacrepairaftermyocardialinfarction
AT junxie cd248targetedbbirtcelltherapyagainstlateactivatedfibroblastsincardiacrepairaftermyocardialinfarction